Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 29, 2022

Tolerability of an Induction Dose Escalation of Everolimus in Patients With Metastatic Breast Cancer



Additional Info

Disclosure statements are available on the authors' profiles:

A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)
ESMO Open 2022 Nov 07;7(6)100601, M Schmidt, K Lübbe, T Decker, M Thill, L Bauer, V Müller, T Link, J Furlanetto, M Reinisch, C Mundhenke, O Hoffmann, MO Zahn, L Müller, C Denkert, M van Mackelenbergh, PA Fasching, N Burchardi, V Nekljudova, S Loibl

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading